Timothy von Fange, MD
Sports Medicine · Columbus, INNPI 1154461739
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 48 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by Novo Nordisk at 31.9% of the total. Reporting peaked in 2020 at $392 and has fallen 83.0% since, to $67 in 2025.
Across 48 payments — averaging $13.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$213
- Bioventus LLC$57
- Lilly USA, LLC$43
- Johnson & Johnson$41
- Boston Scientific$32
- Ferring Pharmaceuticals Inc.$30
- plus $251 from 13 others
What the payments were for
- Food & beverage$667100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 20 | $213 |
| Bioventus LLC | 3 | $57 |
| Lilly USA, LLC | 3 | $43 |
| Johnson & Johnson | 2 | $41 |
| Boston Scientific | 1 | $32 |
| Ferring Pharmaceuticals Inc. | 2 | $30 |
| GSK | 2 | $30 |
| Averitas Pharma Inc. | 1 | $26 |
| Boehringer Ingelheim | 2 | $23 |
| AstraZeneca | 2 | $23 |
| Sanofi-aventis U.S. LLC | 2 | $23 |
| Hydrocision, Inc. | 1 | $21 |
| Astellas Pharma US Inc | 1 | $19 |
| Ultragenyx Pharmaceutical Inc. | 1 | $17 |
| Daiichi Sankyo Inc. | 1 | $17 |
| Genentech USA, Inc. | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| Sanofi Pasteur Inc. | 1 | $12 |
| Merck | 1 | $11 |
How this compares
$667 in reported general payments places this provider in the 55th percentile of 156 sports medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Diclofenac Sodium | 37 | $377 |
| Gabapentin | 15 | $265 |
| Cyclobenzaprine Hcl | 27 | $106 |
| Prednisone | 13 | $42 |
Paid to pharmacies, not to this prescriber.
Other sports medicine in Columbus
- Eric TannenbaumColumbus$14K
- Sean WilsonColumbus$12K
- Cary GuseColumbus$5K
- Jorge ChahlaMunster$917K
- Sean CallowayGreenwood$130K
- Ryan NixonGreenwood$62K
- Tyler McCarrollCarmel$60K
- Nedal AlkhatibIndianapolis$51K
- Stephen ShivelyGreenfield$51K
- Dale SneadCarmel$45K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.